EUVIMEDEUVIMED entdecken
Open Access

Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations

Sumit Bansal, Mary F Paine, Jashvant D Unadkat

Drug Metabolism and Disposition · 2025

DOI: 10.1016/j.dmd.2025.100096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2025. Verfasst von Sumit Bansal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Dronabinol, Models, Biological, Cannabidiol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCCIH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported the inhibitory potential of the most extensively studied cannabinoids, cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), along with their respective circulating metabolites, against a panel of cytochrome P450 (CYP) enzymes. In the current work, we characterized the inhibitory potential of these cannabinoids against a panel of recombinant human UDP-glucuronosyltransferases (UGTs). Upon screening CBD, THC, and their primary circulating metabolites (7-hydroxy CBD or 11-hydroxy THC) at 10 μM, cannabinoids likely to inhibit UGTs at pharmacologically relevant concentrations in vivo were characterized further. The unbound IC50 (IC50,u) for CBD, 7-hydroxy CBD, and THC, respectively, was 0.0015, 1.61, and 0.066 μM (UGT1A9); 0.015, 0.56, and 0.13 μM (UGT2B4); and 0.011, 1.28, and 0.071 μM (UGT2B7). The IC50,u for CBD against UGT1A4, 1A6, 2B10, and 2B15 was 1.22, 0.67, 0.49, and 0.56 μM, respectively. Using various established static models (using Cave,sys,u, Cmax,sys,u, or Cmax,hepatic inlet,u), the predicted magnitude of in vivo hepatic interaction (ratio of the area under the plasma concentration vs. time curve [area under the curve] of the object drug in the presence to absence of cannabinoid) between CBD (700 mg bid oral) and a putative object drug that is extensively metabolized (fm = 0.75) by UGT1A9, 2B4, and 2B7 ranged from 2.2-3.9, 1.3-3.0, and 1.3-3.2, respectively. The physiologically based pharmacokinetic model predicted increase in the area under the curve of dapagliflozin (UGT1A9 substrate; fm = 0.80) and zidovudine (UGT2B7 substrate; fm = 0.70) was 126% and 30%, respectively, upon multiple oral dosing of CBD (700 mg bid). In vivo drug interaction studies using UGT1A9, 2B4, and 2B7 probe drugs are necessary to verify our pharmacokinetic CBD-drug interaction predictions. SIGNIFICANCE STATEMENT: This study represents a comprehensive determination of the potency (IC50,u) of cannabidiol, Δ9-tetrahydrocannabinol, and their metabolites as inhibitors of recombinant human UDP-glucuronosyltransferases. Among these cannabinoids, cannabidiol was the most potent inhibitor of UGT1A9, 2B4, and 2B7. Using static and physiologically based pharmacokinetic models, we predicted weak to moderate pharmacokinetic interactions between chronic cannabidiol (but not Δ9-tetrahydrocannabinol) administration and object drugs predominantly metabolized by UGT1A9, 2B4, or 2B7.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucuronosyltransferaseDronabinolModels, BiologicalCannabidiolCannabinoidsHumansDrug InteractionsMicrosomes, LiverComputer SimulationAnimalsMale

Stichwörter der Autor:innen

CannabinoidsDrug−drug interactionsIn vitro to in vivo prediction of cannabinoid-drug interactionsPhysiologically based pharmacokinetic modelingUridine 5′-diphosphoglucuronosyltransferasescannabidiolΔ(9)-tetrahydrocannabinol

Substanzen

GlucuronosyltransferaseDronabinolCannabidiolCannabinoids

Autor:innen und Institutionen

  • Department of Pharmaceutics, University of Washington, Seattle, Washington.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, Washington; Center of Excellence for Natural Product Drug Interaction Research, Washington St…
  • Department of Pharmaceutics, University of Washington, Seattle, Washington; Center of Excellence for Natural Product Drug Interaction Research, Washington State University, Spokane, Washington. Electronic address: jash@…

Förderung

  • NIDA NIH HHS
  • NCCIH NIH HHS

Zitieren

APA

Bansal, S., Paine, M. F., & Unadkat, J. D. (2025). Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100096

Vancouver

Bansal S, Paine MF, Unadkat JD. Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations. Drug Metabolism and Disposition. 2025. doi:10.1016/j.dmd.2025.100096

BibTeX
@article{Bansal2025,
  author = {Bansal, Sumit and Paine, Mary F and Unadkat, Jashvant D},
  title = {Predicting in vivo cannabinoid-drug interactions mediated via inhibition of UDP-glucuronosyltransferases using in vitro studies and physiologically based pharmacokinetic modeling and simulations},
  journal = {Drug Metabolism and Disposition},
  year = {2025},
  doi = {10.1016/j.dmd.2025.100096}
}
Kostenlos starten →